Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
A subsidiary of Indian drugmaker Hetero Group mistakenly packaged two types of antidepressants in packs of sertraline, potentially posing risks to patients.
Original title: “Sertraline manufacturer recalls antidepressant batch after UK packaging mix-up”
As Q1 earnings roll in, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least partly on novel assets for obesity.
Original title: “Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in”
Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include frontotemporal dementia, is exploring strategic alternatives in addition to cutting staff.
Original title: “Passage cuts 75% of workforce after FDA trial design request”
In its latest biopharma pipeline report, Deloitte warned that the growing importance of a small pool of potential mega-blockbusters raises the risk of “significant value destruction from a single program failure.”
Original title: “Obesity ends oncology’s long reign as top contributor to biopharma pipeline value”
The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.
Original title: “UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases”
Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.
Original title: “What is your AI drug repurposing strategy missing?”
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.
Original title: “Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal”
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.
Original title: “Moderna sees revenue bump from international COVID vaccine sales”
The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.
Original title: “Novartis unveils North Carolina API plant as final piece of $23B US expansion”
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
Original title: “Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook”
CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s return to prosperity.
Original title: “Moderna beats revenue expectations with $389M, but litigation dogs earnings”
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or more infrequent dosing schedules.
Original title: “Amgen positions MariTide as potential ‘best monthly’ obesity drug”